Oligometastatic prostate cancer: a new horizon for robotic radical prostatectomy

Abstract

The advent of modern diagnostic techniques and improved patient monitoring in the setting of clinical trials has led to an increased diagnosis of oligometastatic prostate cancer (OMPC), defined as three-to-five metastatic deposits in a single organ or multiple organs. OMPC is increasingly diagnosed in men who were in the past considered to have organ-confined disease. OMPC occurs at the transition between localized prostate cancer and widespread metastases. Our review evaluates the available evidence regarding robot-assisted cytoreductive prostatectomy feasibility and oncological outcomes in oligometastatic settings. We also consider the limitations and future directions for this approach. We performed a non-systematic PubMed and Google Scholar search. We screened pertinent studies published from 2014 up to May 2021. Our search identified 524 records. After excluding duplication, 54 full-text articles were identified and were screened for eligibility. We found nine papers (863 patients) that met the inclusion criteria for the review. The outcomes evaluated were 1-, 3-, and 5-year progression-free survival, cancer-specific and overall survival rates. Our review article demonstrates the feasibility and safety of Robot-assisted radical prostatectomy in patients with OMPC with proven oncological benefits. Prospective studies are ongoing and may provide further solid evidence.

Keywords

Oligometastatic prostate cancer / robotic radical prostatectomy / metastatic prostate cancer / localized prostate cancer

References

[1] Khoo V.Is there another bite of the cherry?.Eur Urol2016;69:13-4

[2] Evangelista L,Fanti S.New clinical indications for (18)F/(11)C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: a systematic review of the literature.Eur Urol2016;70:161-75

[3] Ost P,Decaestecker K.Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial.J Clin Oncol2018;36:446-53

[4] Gravis G,Chen YH.Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies.Eur Urol2018;73:847-55 PMCID:PMC6010352

[5] Parker CC,Brawley CD.Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.Lancet2018;392:2353-66 PMCID:PMC6269599

[6] Singh D,Brasacchio RA.Is there a favorable subset of patients with prostate cancer who develop oligometastases?.Int J Radiat Oncol Biol Phys2004;58:3-10

[7] Heidenreich A,Pfister D.Cytoreductive radical prostatectomy in men with prostate cancer and skeletal metastases.Eur Urol Oncol2018;1:46-53

[8] Cornford P,Bolla M.EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer.Eur Urol2017;71:630-42

[9] Mathieu R,Bensalah K,Shariat SF.Cytoreductive radical prostatectomy in metastatic prostate cancer: does it really make sense?.World J Urol2017;35:567-77

[10] Morrow M.Surgery of the primary tumor in metastatic breast cancer: closing the barn door after the horse has bolted?.J Clin Oncol2006;24:2694-6

[11] Sooriakumaran P,Stief C.A Multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation.Eur Urol2016;69:788-94

[12] Jang WS,Jeong WS.Does robot-assisted radical prostatectomy benefit patients with prostate cancer and bone oligometastases?.BJU Int2018;121:225-31

[13] Culp SH,Williams MB.Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor?.Eur Urol2014;65:1058-66

[14] Gandaglia G,Stabile A.Radical prostatectomy in men with oligometastatic prostate cancer: results of a single-institution series with long-term follow-up.Eur Urol2017;72:289-92

[15] Satkunasivam R,Desai M.Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-Medicare analysis.J Urol2015;194:378-85 PMCID:PMC4834920

[16] Gratzke C,Stief CG.Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry.Eur Urol2014;66:602-3

[17] Antwi S.Prognostic impact of definitive local therapy of the primary tumor in men with metastatic prostate cancer at diagnosis: a population-based, propensity score analysis.Cancer Epidemiol2014;38:435-41

[18] Poelaert F,Rappe B.Cytoreductive prostatectomy for metastatic prostate cancer: first lessons learned from the multicentric prospective local treatment of metastatic prostate cancer (LoMP) trial.Urology2017;106:146-52

[19] Wagaskar VG,Sobotka S.Hood technique for robotic radical prostatectomy-preserving periurethral anatomical structures in the space of Retzius and Sparing the pouch of Douglas, enabling early return of continence without compromising surgical margin rates.Eur Urol2021;80:213-21

[20] Saika T,Fukumoto T,Miyauchi Y.Role of robot-assisted radical prostatectomy in locally advanced prostate cancer.Int J Urol2018;25:30-5

[21] Tzelepi V,Wen S.Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.J Clin Oncol2011;29:2574-81 PMCID:PMC3138635

[22] Shemshaki H,Geelani IA.Cytoreductive radical prostatectomy versus systemic therapy and radiation therapy in metastatic prostate cancer: a systematic review and meta-analysis.Urologia2022;89:16-30

[23] Preisser F,Nazzani S.Comparison of perioperative outcomes between cytoreductive radical prostatectomy and radical prostatectomy for nonmetastatic prostate cancer.Eur Urol2018;74:693-6

[24] Checcucci E,De Luca S,Fiori C.Precision prostate cancer surgery: an overview of new technologies and techniques.Minerva Urol Nefrol2019;71:487-501

[25] Sooriakumaran P.Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomized controlled feasibility trial.BJU Int2017;120:E8-E20